Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery
- Conditions
- Cardiac Surgery
- Interventions
- Drug: Intravenous Crystalloid
- Registration Number
- NCT02757118
- Lead Sponsor
- Konkuk University Medical Center
- Brief Summary
After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing cardiac surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15).
All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department.
According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture.
Patient data and statistical analyses:
Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge.
All statistical analyses will be performed after the 30th patient's discharge and data acquisition
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
- Patients undergoing coiling embolization procedure due to cardiac surgery
- Patients provided a written informed consent.
- Patients with preoperative serum hemoglobin concentration >13 g/dL (male) and >12 g/dL (female)
- Patients with PaO2/FiO2 ratio >150
- Patients with history of anemia, dyspnea, active infection.
- Patients with endocrine disease
- Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-platelet drug, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing cardiac surgery.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intravenous Crystalloid Intravenous Crystalloid crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture Intravenous HES Intravenous HES HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
- Primary Outcome Measures
Name Time Method whole blood viscosity with 1 hour after the completion of procedure
- Secondary Outcome Measures
Name Time Method hematocrit with 1 hour after the completion of procedure serum hematocrit, %
PaO2/FiO2 ratio with 1 hour after the completion of procedure PaO2/FiO2 ratio measured by arterial blood gas analysis
glucose with 1 hour after the completion of procedure serum glucose level, g/dl
osmolarity with 1 hour after the completion of procedure serum osmolarity, mOsm
urine output with 1 hour after the completion of procedure hourly urine output, ml/hr
Maximum clot formation with 1 hour after the completion of procedure Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm